Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on TRITAX BIG BOX REIT PLC. We currently have 2 research reports from 2 professional analysts.
|07Mar17 07:00||RNS||FULL YEAR RESULTS|
|07Mar17 07:00||RNS||Dividend Declaration|
|01Mar17 07:00||RNS||New Fixed Rate Term Loan Facility of £90 Million|
|22Feb17 07:00||RNS||Forward funded investment|
|07Feb17 07:00||RNS||Notice of Results|
|19Jan17 07:00||RNS||Trading Statement|
|23Dec16 07:00||RNS||FORWARD FUNDED INVESTMENT|
Frequency of research reports
Research reports on
TRITAX BIG BOX REIT PLC
TRITAX BIG BOX REIT PLC
Listed Real Estate
20 May 16
There are suggestions that the sector has peaked, but we feel this relates more to Central London than the rest of the country: the EU referendum has certainly provided an excuse to ‘wait and see’, compounding the effect of any uncertainty. Activity levels have suffered and the growth momentum slowed, and this is now showing up clearly in market data. However, the impact is not universal and is concentrated on the more exposed investment areas of Central London, leaving bright spots across the sector for investors to exploit.
Debt & renewables dominate
09 Jan 14
A total of £3.1bn was raised in the funds sector in the fourth quarter of 2013, exceeding total funds raised for the whole of 2012 (£2.7bn). The alternative asset and income theme continued to dominate, with most successful vehicles offering yields in excess of 5%.
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.